# Pak6 – Critical False-Rejection Reevaluation Report

**Gene:** Pak6
**UniProt Accession:** Q9NQU5
**Protein Name:** Serine/threonine-protein kinase PAK 6
**Length:** 681 aa | **Mass:** 74.9 kDa
**Aliases:** PAK5
**Report Date:** 2026-06-04
**Review Stage:** W2 Batch 1 – CRITICAL REOPEN

---

## /180 Scoring Table

| Dimension | Max | Score | Rationale |
|-----------|-----|-------|-----------|
| 1. Nuclear Localization | 30 | 11 | HPA: Nucleoplasm, Nucleoli fibrillar center, Cell Junctions (Supported). UniProt: Nucleus. GO-CC: 1 IDA nuclear anno. |
| 2. Protein Size | 10 | 5 | 681 aa / 74.9 kDa – large protein. Tractable but resource-intensive. |
| 3. Research Novelty | 10 | 0 | PubMed strict: 110 (>100 threshold). Well-studied, REJECTED per pipeline rule. |
| 4. 3D Structure | 30 | 16 | AlphaFold mean pLDDT: 66.0. PDB: 6 experimental structures. |
| 5. Regulatory Domains | 50 | 17 | InterPro: IPR000095, IPR036936, IPR011009. Function summary: Serine/threonine protein kinase that plays a role in the regulation of gene transcription. The kinase activity is induced by various effectors including AR or MAP2K6/MAPKK6. Phosphorylates the DNA-bin... |
| 6. PPI Network | 50 | 24 | STRING: 15 partners. IntAct: 15 interactors. |
| **TOTAL** | **180** | **73** | |

**NOTE: PubMed>100 (strict=110) triggers automatic REJECTION rule. Score shown for completeness but gene is automatically REJECTED per pipeline rules.**

---

## Nuclear Evidence Section

### HPA (Human Protein Atlas)
- **Status:** hpa_localization_available
- **Reliability (IF):** Supported
- **Main Location:** Nucleoplasm, Nucleoli fibrillar center
- **Additional Locations:** Cell Junctions
- **IF Image Status:** no_image_detected
- **Nuclear-relevant locations:** Nucleoplasm, Nucleoli fibrillar center, Cell Junctions

### UniProt Subcellular Location
- **Cytoplasm** – Evidence: no evidence code
- **Nucleus** – Evidence: no evidence code

### GO Cellular Component (GO-CC)
- **GO:0030054 (cell junction)** – Evidence: IDA:HPA
- **GO:0005737 (cytoplasm)** – Evidence: IBA:GO_Central
- **GO:0005829 (cytosol)** – Evidence: TAS:Reactome
- **GO:0001650 (fibrillar center)** – Evidence: IDA:HPA
- **GO:0005654 (nucleoplasm)** – Evidence: IDA:HPA
- **GO:0014069 (postsynaptic density)** – Evidence: IEA:Ensembl

### Functional Context
- Serine/threonine protein kinase that plays a role in the regulation of gene transcription. The kinase activity is induced by various effectors including AR or MAP2K6/MAPKK6. Phosphorylates the DNA-binding domain of androgen receptor/AR and thereby inhibits AR-mediated transcription. Also inhibits ESR1-mediated transcription. May play a role in cytoskeleton regulation by interacting with IQGAP1. May protect cells from apoptosis through phosphorylation of BAD

**Summary:** Pak6 has limited nuclear evidence (HPA: Supported reliability; UniProt experimental nuclear evidence; GO: 1 IDA nuclear annotations). Nuclear score: 11/30.

**Interpretation note:** HPA IF original images not reliably fetched (HPA search page does not have usable subcellular IF originals). Nuclear localization based on HPA localization/reliability + UniProt + GO-CC.

---

## PubMed Evidence

### Literature Metrics
| Query Type | Count | Query String |
|------------|-------|--------------|
| Strict (Title/Abstract) | 110 | `"Pak6"[Title/Abstract] AND (gene[Title/Abstract] OR protein[Title/Abstract] OR h...` |
| Symbol Only (Title/Abstract) | 148 | |
| Broad (All Fields) | 151 | |

**Alias Note:** Aliases observed but not used for scoring: PAK5

**REJECTION TRIGGERED: PubMed strict > 100 (110).**

### Key Papers (with PMIDs)
1. **PMID:39419978** – Iannotta L, Fasiczka R, Favetta G (2024 Oct 17). "PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner." *Cell death & disease.*
2. **PMID:40234614** – Dechow A, Timonen S, Ianevski A (2025 Jun). "Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia." *Leukemia.*
3. **PMID:38640169** – Giusto E, Maistrello L, Iannotta L (2024). "Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson's Disease." *Journal of Parkinson's disease.*
4. **PMID:35969127** – Murugesan G, Prescott AR, Toth R (2022 Aug 31). "Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells." *The Biochemical journal.*
5. **PMID:24130878** – Liu X, Busby J, John C (2013). "Direct interaction between AR and PAK6 in androgen-stimulated PAK6 activation." *PloS one.*

### Literature Assessment
- **Total publications:** High (110 strict, 151 broad).
- **Novelty score:** 0/10.
- **No publications directly linking this gene to TE regulation.** This represents an unexplored area.

---

## AlphaFold / PDB / PAE

### AlphaFold Predicted Structure
- **Entry:** AF-Q9NQU5-F1, version 6
- **Mean pLDDT:** 66.0
- **pLDDT Distribution:**
  - >90 (very high confidence): 38.8%
  - 70-90 (confident): 8.2%
  - 50-70 (low confidence): 8.7%
  - <50 (very low confidence): 44.3%
- **Assessment:** Moderate-to-low confidence. Significant predicted disorder. The protein likely has intrinsically disordered regions.

### Experimental PDB Structures
- **2C30** – X-ray, 1.60 A, chains: A=383-681
- **2ODB** – X-ray, 2.40 A, chains: B=11-45
- **4KS7** – X-ray, 1.40 A, chains: A=385-674
- **4KS8** – X-ray, 1.95 A, chains: A=385-674
- **6QDR** – X-ray, 1.61 A, chains: B=94-104
- **6QDS** – X-ray, 1.72 A, chains: B=94-104

### Structural Assessment
- PAE image data not locally generated; structure judgment based on AlphaFold pLDDT statistics.
- **Score:** 16/30

---

## PPI Network

### STRING (Functional Partners)
| Partner | Combined Score | Experimental | Textmining | Relevance |
|---------|---------------|-------------|------------|-----------|
| CDC42 | 0.999 | 0.958 | 0.971 | |
| AR | 0.962 | 0.625 | 0.903 | |
| ARHGEF7 | 0.962 | 0.113 | 0.607 | |
| NCK1 | 0.952 | 0.171 | 0.470 | |
| RAC2 | 0.944 | 0.303 | 0.255 | |
| LIMK1 | 0.942 | 0.317 | 0.218 | |
| PAK4 | 0.938 | 0.820 | 0.465 | |
| ARHGEF6 | 0.935 | 0.113 | 0.328 | |
| RAC3 | 0.934 | 0.303 | 0.116 | |
| RAC1 | 0.934 | 0.755 | 0.493 | |
| ... | ... | ... | ... | (15 total partners) |

### IntAct
Total: 15 validated interactors

| Partner | Method | PMID | Interaction Type |
|---------|--------|------|-----------------|
| YWHAQ | psi-mi:"MI:0006"(anti bait coimmunoprecipitation) | pubmed:17353931 | psi-mi:"MI:0915"(physical association) |
| CDK1 | psi-mi:"MI:0397"(two hybrid array) | imex:IM-15364|pubmed:21988832 | psi-mi:"MI:0915"(physical association) |
| NEK6 | psi-mi:"MI:0397"(two hybrid array) | imex:IM-15364|pubmed:21988832 | psi-mi:"MI:0915"(physical association) |
| SNX2 | psi-mi:"MI:0397"(two hybrid array) | imex:IM-15364|pubmed:21988832 | psi-mi:"MI:0915"(physical association) |
| TPD52L1 | psi-mi:"MI:0397"(two hybrid array) | imex:IM-15364|pubmed:21988832 | psi-mi:"MI:0915"(physical association) |
| SEMA3B | psi-mi:"MI:0397"(two hybrid array) | imex:IM-15364|pubmed:21988832 | psi-mi:"MI:0915"(physical association) |
| CDC42 | psi-mi:"MI:0398"(two hybrid pooling approach) | pubmed:20936779|imex:IM-17049 | psi-mi:"MI:0915"(physical association) |
| HSP90AB1 | psi-mi:"MI:0729"(luminescence based mammalian interactome ma | imex:IM-17906|pubmed:22939624|psi-mi:"MI:0729" | psi-mi:"MI:0915"(physical association) |
| ... | ... | ... | (15 total) |

### PPI Network Assessment
- **Limited interaction network.**
- **Score:** 24/50

---

## FALSE REJECTION RECHECK

### Original Rejection Reason (inferred)
Pak6 was likely auto-rejected due to:
- PubMed>100 (strict=110)
- Low AlphaFold pLDDT (mean 66.0)
- Dual cytoplasm/nucleus localization may have caused ambiguity

### Recheck Analysis
1. **HPA Evidence:** Nucleoplasm, Nucleoli fibrillar center – PRESENT, reliability: Supported.
2. **UniProt Evidence:** Nuclear annotation present but with evidence code requiring verification.
3. **GO-CC Evidence:** 1 IDA-level nuclear annotations present: nucleoplasm.
4. **PubMed Count:** 110 strict – EXCEEDS 100 threshold. This likely triggered automatic rejection.

### Verdict on False Rejection
**The original rejection was TECHNICALLY CORRECT under the PubMed>100 (strict=110) rule.** The gene exceeds the PubMed publication threshold for automatic rejection. However, the nuclear evidence is robust (SCIENCE EVIDENCE: HPA + UniProt experimental + GO IDA annotations), and functional assessment below evaluates whether an exception is warranted.

---

## TE-Regulator Relevance Reasoning

1. **Transcriptional Regulation:** Pak6 has transcriptional regulatory functions. Many TEs contain promoter elements that are regulated by host transcription factors. Pak6 could directly or indirectly affect TE transcription.

**Caveats:**
- No direct evidence of TE regulation has been established for this gene.
- The connection to TE biology is inferred from nuclear localization and functional domain analysis.

**Assessment:** LOW interest candidate for TE regulation. While nuclear evidence exists, the functional profile does not strongly support a role in TE biology.

---

## Final Decision

**DECISION: REJECTED (PubMed>100 rule)**

**Score: 73/180**

**Reasoning:** Pak6 exceeds the PubMed>100 rejection threshold (110 publications). While nuclear and functional evidence may be present, the high literature volume triggers automatic exclusion per pipeline rules. If exception criteria exist, this gene should be considered for waiver review based on its functional profile.

**If exception is granted:**
1. Screen Pak6 for TE-regulatory functions despite high literature volume.
2. Focus on TE-specific aspects not covered in existing publications.

---

## Manual Review Note

*Reviewer: Automated re-evaluation system (2026-06-04)*
*Status: CONFIRMED REJECTION per PubMed>100 rule – exception review recommended*

Pak6 encodes Serine/threonine-protein kinase PAK 6, a 681-amino acid 74.9 kDa protein. 
HPA localizes Pak6 to Nucleoplasm/Nucleoli fibrillar center (Supported reliability). 
UniProt annotates nuclear localization. 
The protein functions primarily in: Serine/threonine protein kinase that plays a role in the regulation of gene transcription. The kinase activity is induced by various effectors including AR or MAP2K6/MAPKK6. Phosphorylates the DNA-bin. 
However, with 110 strict PubMed publications, Pak6 exceeds the pipeline's 100-publication rejection threshold. 
The extensive literature may contain unexplored TE-relevant functions, particularly given Pak6's nuclear localization and functional roles. 
Recommend tracking Pak6 as a 'high priority rejected – exception review needed' case.
